NeuroSense Therapeutics Ltd

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Allego NV

Alpha Tau Medical

Forge Global Holdings Inc

Leafly Holdings

JX Luxventure Ltd

Miromatrix Medical Inc

Kidpik Corp

Society Pass

SciSparc Ltd

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore, and bring order to the markets.

12 Stocks Halted On A Circuit Breaker This Week

- Warrants exercised at $6 per share - Extends cash runway through Q3 2023 CAMBRIDGE, Mass., March 25, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Receives $4 Million Through Warrant Exercises

Neurosense Therapeutics Ltd (NASDAQ:NRSN) tripled market value in a day. This was after announcing approval by the US Food and Drugs Authority to advance research on a drug for Amyotrophic Lateral Sclerosis.

Neurosense multiplies investor value 3X. Buy the penny stock and wait

A thumbs up from the FDA has NRSN stock surging. Here's what this victory means for NeuroSense and for investors.

Why Is NeuroSense Therapeutics (NRSN) Stock Up 300% Today?

Camber Energy

Cenntro Inc

Check these three penny stocks out for your watchlist right now The post Hottest Penny Stocks To Watch as March Comes to an End  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hottest Penny Stocks To Watch as March Comes to an End

NeuroSense Therapeutics Ltd (NASDAQ: NRSN) has received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.  PrimeC is a novel extended-release oral formulation composed of a fixed-dose combination of ciprofloxacin and celecoxib.

NeuroSense Shares Surge Over 400% As FDA Clears Initiating Pharmacokinetic Study Of PrimeC

NeuroSense Therapeutics Ltd (NASDAQ: NRSN) shares are soaring Monday after the company announced it received U.S. Food and Drug Administration clearance to initiate a pharmacokinetic study of PrimeC in healthy adult subjects. PrimeC is designed to synergistically target.

Why NeuroSense Shares Are Soaring Today

CAMBRIDGE, Mass. , March 21, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS

CAMBRIDGE, Mass., March 15, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m.

CAMBRIDGE, Mass., March 1, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Granted Key Patent for its ALS Drug PrimeC in Australia

Nordic American Tankers

Zomedica

Add these penny stocks to your March 2022 watchlist The post Top Penny Stocks to Buy in March 2022, 3 For Your List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy in March 2022, 3 For Your List

CAMBRIDGE, Mass., Feb. 24, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Present at American Society for Experimental Neurotherapeutics Annual Meeting on March 3rd

CAMBRIDGE, Mass., Feb. 22, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Present at Aegis Virtual Conference

CAMBRIDGE, Mass., Jan. 31, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics to Present at BIO CEO & Investor Conference

CAMBRIDGE, Mass., Jan. 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Extends ALS Biomarker Collaboration with Massachusetts General Hospital

CAMBRIDGE, Mass., Jan. 4, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics, Ltd. Announces the Presentation of Phase IIa Study Results at Four International Conferences

NeuroSense Therapeutics is advancing a breakthrough treatment for ALS and other neurodegenerative diseases. The Company's approach is to target the multiple disease mechanisms in the CNS by combining therapeutic strategies.

NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases

CAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. Expands Board of Directors and Adds Chief Medical Officer to Leadership Team

CAMBRIDGE, Mass., Dec. 13, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Announces Closing of Initial Public Offering on Nasdaq Capital Market

News for NeuroSense Therapeutics Ltd Stock (NRSN)